PRPH ProPhase Labs Corp Full Business Value

Official company branding of ProPhase Labs Corp (PRPH)

ProPhase Labs, Inc. (PRPH) leverages the synergy between specialized geneticists and diagnostic experts to create an environment for rapid career growth. The business is based on moderately cyclical laboratory services and the sale of dietary supplements, where an autumn peak offsets the volatility in testing demand. The current metric stands at 9.45. This price action chart confirms the company's macro resilience, which depends on the rollout of new products and the success of clinical trials.

PRPH (ProPhase) Total Company Value history from 11/23/2025 to 01/10/2026

PRPH (ProPhase Labs, Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Performance Chart ProPhase Labs Inc|PRPH - Price Target Chart
- market capitalization data:
Market Valuation ProPhase Labs|PRPH - Enterprise Value
- book capitalization data:
Accounting Value of a Share ProPhase Labs|PRPH - Company Book Value|Market Cap to Net Assets Ratio prophaselabs.com|PRPH - Company Total Assets
- debt and liquidity data:
Debt to Capital ProPhase Labs, Inc.|PRPH - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio prophaselabs.com|PRPH - Company Aggregate Debts|Debts to Book Capitalization ProPhase Labs
Summary company analytics:ProPhase Labs Inc (PRPH)
Original product of ProPhase Labs Inc

Investors are seeking a fundamental anchor in the business resilience of ProPhase Labs, Inc. (PRPH), yet reliance on post-pandemic diagnostic demand and genomics expenditures create risks of profit degradation. The enterprise value reflects the total cost of the asset by summing market capitalization and net debt. The current value of 9.45 allows for an assessment of the actual costs of acquiring the company. A decline in this indicator often signals a loss of liquidity and market attractiveness.

Competitor analysis

Agilent Technologies, Inc. - Value Adjusted for Debt and Cash|Total Company Value Quest|ILMN - Full Business Value|Enterprise Value Exact Sciences EXAS|RVTY (revvity.com) - Value Adjusted for Debt and Cash|Total Company Value BIO|Real Price to Acquire Entire Company Anbio Biotechnology Ltd|Sterigenics - Enterprise Value|Total Enterprise Value QuidelOrtho Inc. (QDEL)|OPK - Enterprise Value|Business Value CareDx Health CDNA|Maravai LifeSciences Holdings, Inc. - Enterprise Value|FLGT: Enterprise Value|Total Company Value Fluidigm|Cytek Corp (CTKB) - Business Value|OSUR (OraSure Technologies) - Enterprise Value|Enterprise Value XGN|Total Company Value MDxHealth (MDXH)|Total Company Value Lucid Diagnostics, Inc. LUCD|PRE: Real Price to Acquire Entire Company|Insight Molecular Diagnostics, Inc. - Total Enterprise Value|Total Company Value TRIB (Trinity Biotech Corp)|AIMD - Company Buyout Price|Co-Diagnostics - Enterprise Value|HSCS (Heart Test Laboratories, Inc.) - Company Buyout Price|BMRA: Total Company Value|Company Buyout Price CDIO|VRAX - Total Company Value|Full Business Value BJDX (bluejaydx.com)|Total Company Value Aspira Women's Health Inc.|Accelerate Diagnostics Inc. - Value Adjusted for Debt and Cash|CNTG (Centogene) - Total Company Value|ENZ: Total Enterprise Value|Total Company Value fresh2.co (FRES)|Genetic Technologies Limited (GENE) - Full Business Value|ME - Enterprise Value|Value Adjusted for Debt and Cash Psychemedics Corp.